Xeomin is used to treat cervical dystonia (severe spasms in the neck muscles) and certain eye muscle conditions caused by nerve disorders. This includes uncontrolled blinking or spasm of the eyelids, and a condition in which the eyes do not point in the same direction.
Xeomin is also used to temporarily lessen the appearance of facial wrinkles (sometimes called "frown lines") between the eyebrows.
What is XEOMIN®?
Xeomin® is approved for the temporary improvement in the appearance of glabellar lines in 14 countries in the European Union (EU), including Germany, the United Kingdom, France, Italy and Spain, under the brand name Bocouture®.
XEOMIN® is a prescription medication used in facial aesthetics to temporarily improve the appearance of moderate to severe glabellar frown lines between the eyes (glabellar lines) in adults.
XEOMIN® contains botulinum toxin type A, a protein purified from the bacterium Clostridium botulinum.
XEOMIN® is also sometimes referred to as incobotulinumtoxinA.
XEOMIN® in Aesthetics: How Does it Work?
When you squint or frown, the muscles between your brows contract, causing the skin to furrow and fold. These lines that occur due to facial mimics are referred to as dynamic lines. Over time, as your skin ages and loses some of its elasticity, these repeated contractions can cause persistent frown lines.
Botulinum toxin type A – the active ingredient in XEOMIN® – is used in facial aesthetic treatment to treat dynamic lines like glabellar frown lines. It acts on nerve endings in muscles to prevent muscle fibers from contracting. By reducing these contractions, XEOMIN® can temporarily reduce the frown lines on your forehead between your eyes.
Xeomin vs. Botox vs. Dysport
- After a 10 month injunction, Xeomin is again being launched in the US as a treatment of glabellar lines
- The main difference between Xeomin and Botox or Dysport, is that Xeomin contains just one ingredient: botulinum toxin A.
- Xeomin is a “naked injectable,” meaning that it does not contain any additives. A benefit of a pure-form injectable is that the human body is less likely to become resistant to it.
- Xeomin is the only one of the three (Xeomin, Botox and Dysport) that does not need to be refrigerated before use.
- The cost of Xeomin is anticipated to be slighly less expensive than for Botox and about the same as Dysport per unit.
- Patients average 20 units of Xeomin per visit, vs. 20 units of Botox and 40 units of Dysport.
- Xeomin might have the slowest “onset” of action of the 3 (Dysport onset in 24 hours, Botox onset in 72 hours, and Xeomin onset in 4 days.)
- Xeomin may be “mildly more convenient” than Botox or Dysport, as the “product’s lack of complex proteins will help prevent antibody formation, or resistance to neuromuscular treatment with botulinum type A toxin, in patients being treated for neuromuscular conditions.”
Xeomin has available outside the US since 2005, and was introduced in the US in 2010. Xeomin was given the FDA approval in July 2011 for the treatment of cervical dystonia, blepharospasm, and glabellar lines, but an injuction halted the release. Now, after a 10 month injunction, Xeomin is again being launched in the US as a treatment of glabellar lines. Xeomin®, by Merz Pharmaceuticals LLC, is a competitor to the well established Botox Cosmetic® and lesser used Dysport®.
Xeomin does not contain any additives. Patients are less likely to become resistant to Xeomin because there are simply less ingredients in the solution. Some patients have developed antibodies to Botox and Dysport.